Rheumatoid Arthritis
Richard Conway RichardPAConway
4 years 1 month ago
@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw
Akhil Sood MD AkhilSoodMD
4 years 1 month ago
Abstr 0579
Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line biologic agent
- Females & GC use more likely to switch agent
- Vitamin D use & hx of other immune-mediated diseases (eg. Psoriasis, IBD) less likely to switch
#ACR21 @RheumNow https://t.co/FM5mSWmSNA
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Eric Dein ericdeinmd
4 years 1 month ago
#ACR21 Abs#0825
Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ)
⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX
⭐️ Radiographic progression low in all
▶️ Short study w very aggressive 1st line combo Rx
https://t.co/TJPZkqmN8z @Rheumnow
Eric Dein ericdeinmd
4 years 1 month ago
#ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs
⭐️More pts stay on UPA vs ADA (47 vs 36%)
⭐️Adverse drug events similar between groups. UPA has ⬆️ zoster, lymphopenia, hepatic and CPK elevations
https://t.co/eLCytSX7Gz @Rheumnow https://t.co/i8NjSgImVq
Aurelie Najm AurelieRheumo
4 years 1 month ago
🩸 Hb levels markers of RA activity and structural progression? Boston BRASS registry: 1500+ patients.
Low hb at headline associated w/ MTX TNFi and ⬆️ increase in TSS.
Not that surprising provided low Hb is a marker of systemic inflammation. #Abtr0786 #ACR21 @Rheumnow https://t.co/eQLGxsANkk
TheDaoIndex KDAO2011
4 years 1 month ago
Can RA be cured?
Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy given by SQ injx; it's presented by LN-DCs causing: CTL exhaustion while controlling autoreactive CD4+ T cells #ACRbest @rheumnow #ACR21
Abst#0967should have been a plenary! https://t.co/6ZzDgavafS
Mrinalini Dey DrMiniDey
4 years 1 month ago
Does #RA treatment affect low Hb levels? Is there a relationship between Hb and radiographic progression?
#ACR21 Abs#0787
👉🏼Sustained improvements in Hb when treated with bio/non-bio DMARDs
👉🏼Low Hb assoc with incr radiographic progression
@RheumNow
https://t.co/DWgoiqYfAt https://t.co/aSRCT2vGjW
Richard Conway RichardPAConway
4 years 1 month ago
@KronzerMD @jeffsparks on association of respiratory diseases with incident RA. Upper airway diseases (sinusitis, pharyngitis) seem to associate even more strongly than asthma/COPD. Abstr#564 #ACR21 @RheumNow https://t.co/HvoBOs3OOF
Richard Conway RichardPAConway
4 years 1 month ago
Dr Mahajan on lung disease in early RA. Common, airway disease in 60%, parenchymal disease in 30%. But minimal/no progression over 1 year which is reassuring. Abstr#574 #ACR21 @RheumNow https://t.co/s9r06MSStF
Richard Conway RichardPAConway
4 years 1 month ago
MUC5B and RA-ILD. Dr McDermott @jeffsparks show that MUC5B is associated with RA-ILD, older age at RA diagnosis, and ILD within 5 years of RA onset. Is this a different disease to other RA or modulation by the promotor variant? Abstr#0576 #ACR21 @RheumNow https://t.co/r2fQqxVY6N
In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials. We often make our choices based on minor hints from clinical features, comorbidities, or cost considerations.
Richard Conway RichardPAConway
4 years 1 month ago
And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 extra MACE per 319-567 patient years, 1 extra malignancy per 275 patient years. Abstr#0831 #ACR21 @RheumNow https://t.co/wMJnspTTBy
Poster Hall